Laprazol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Laprazol

What is Laprazol? (Lansoprazole)

Laprazol is a brand name for the medication lansoprazole, which is used to treat various medical conditions resulting from the production of stomach acid. This medication belongs to the pharmacological group known as Proton Pump Inhibitors (PPIs).

Property Description
Active ingredient Lansoprazole
Form Delayed-release capsules or tablets
Pharmacological class Proton Pump Inhibitor (PPI)
Common use Reducing stomach acid for conditions like heartburn and ulcers
Availability Prescription (Rx) and Over-the-Counter (OTC) at lower doses

Lansoprazole works by decreasing the amount of acid the stomach produces. This helps alleviate symptoms such as frequent heartburn and acid reflux, while also allowing damaged tissues in the esophagus and stomach lining to heal.

The medication is utilized in the management of acid-related disorders, including the healing and relief of symptoms associated with gastro-oesophageal reflux disease (GERD) and peptic ulcers.

Formulations of lansoprazole are available for both short-term prescription use and lower-dose over-the-counter use for the management of frequent heartburn. The medication is recognized for its role in managing symptoms caused by stomach acid production.

Lansoprazole is typically prepared as a delayed-release capsule or tablet. This formulation protects the drug from being neutralized by stomach acid, allowing it to be absorbed and target the acid-producing cells effectively.

What side effects are possible with Laprazol?

Possible Side Effects and Safety Information

The official safety profile for Laprazol (lansoprazole) is structured according to regulatory classifications, detailing observed adverse reactions across various organ systems and frequency categories.

Frequency-Classified Adverse Reactions

Adverse reactions are classified in official documents based on their observed occurrence:

  • Common (occurring in ge 1/100 to < 1/10 patients): These effects primarily involve the gastrointestinal and nervous systems. Documented reactions include headache, dizziness, nausea, diarrhea, abdominal pain, constipation, flatulence, and increased liver enzyme levels.
  • Uncommon (occurring in ge 1/1,000 to < 1/100 patients): Reported effects include depression, muscle pain (myalgia), joint pain (arthralgia), and documented risks of bone fracture in the hip, wrist, or spine.
  • Rare to Very Rare (occurring in < 1/1,000 to < 1/10,000 patients): These reactions include severe blood disorders, pancreatitis, hepatitis, jaundice, confusion, hallucinations, and severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson Syndrome (SJS).

Serious Safety Constraints and Patterns

The regulatory labeling includes specific safety considerations that are often tied to the duration of use or patient status:

  • Duration-Related Risks: Long-term use (typically one year or longer) is officially documented as increasing the risk of osteoporosis-related fractures and the potential for Hypomagnesaemia (low magnesium in the blood). Extended daily use (e.g., three years or more) is also associated with the risk of Vitamin B12 deficiency.
  • Serious Adverse Reactions: The label notes potential for rare, serious events such as Acute Tubulointerstitial Nephritis (a form of kidney inflammation) and an increased risk of Clostridium difficile-associated diarrhea (CDAD).
  • Safety Precaution: Symptomatic response to this medicine does not preclude the presence of underlying gastric malignancy (cancer), a high-level constraint noted in regulatory documents.
  • Population Notes: The medicine is not recommended for use in pediatric patients under one year of age, a specific restriction noted in the official prescribing information.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation mandates that any suspected Laprazol overdose is considered an emergency requiring immediate medical attention. You must contact a Poison Control Center or emergency services immediately if an overdose event is suspected, regardless of the apparent symptoms.

Documented Overdose Profile

The official prescribing information, including the dedicated Overdosage sections from regulatory authorities, does not explicitly list a specific set of acute clinical signs or symptoms.

The required management for an overdose is strictly symptomatic and supportive. The regulatory guidance explicitly confirms that no specific antidote is known for Laprazol overdose. Healthcare providers may implement supportive measures, including gastric emptying and the administration of charcoal, as necessary.

Population-Specific Considerations

Regulatory labeling identifies that certain patient conditions impact the body’s ability to clear the medicine, thereby increasing the risk of elevated exposure during an overdose.

Specifically, individuals with moderate or severe hepatic impairment (liver disease) may experience a potential for greater drug exposure because their bodies exhibit reduced clearance of the active ingredient. This pharmacokinetic difference is noted in the regulatory documents as a factor requiring regular supervision for this population.

This profile summarizes the official, mandate-driven information found within regulatory documents like the Summary of Product Characteristics (SmPC) and FDA Prescribing Information.

Therapeutic Uses of Laprazol

What Laprazol Treats: Main Uses and Benefits

Laprazol is commonly used to provide symptomatic support across several clinical scenarios, assisting patients in coping with discomfort and functional strain during difficult episodes. This medication is applied to help manage symptoms associated with conditions like gastroesophageal reflux disease (GERD), certain types of ulcers, and other conditions involving heightened physiological activity.


Supporting Symptomatic Relief

Laprazol is applied in clinical settings that involve acute or disruptive symptom patterns where symptoms may become intense or disruptive and cause noticeable interference with daily comfort. The medicine may assist patients during difficult episodes, contributing to easing distress, and is relevant for managing symptom clusters that create symptoms that interfere with daily functioning. It offers symptomatic relief that may assist with coping during periods when symptoms become temporarily overwhelming.

“The medicine helps address groups of symptoms that may appear suddenly or intensify over time, supporting general well-being during symptomatic phases.”

Quick Fact: Relevant for Symptoms related to physical discomfort

Laprazol is generally used for conditions involving episodic or fluctuating manifestations or those presenting with recurrent episodes. It supports the patient during episodes of heightened discomfort and is relevant in contexts where short-term symptomatic assistance is appropriate.

Regulatory References

  1. Lansoprazole: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Laprazol?

The official eligibility for Laprazol (lansoprazole) is strictly defined by government regulatory documents, outlining populations permitted for use, those requiring restriction, and groups for whom the medicine is absolutely contraindicated.

Contraindicated Populations

Laprazol must not be used in patients with a known hypersensitivity to lansoprazole or its components. It is also contraindicated for patients concurrently taking specific antiretroviral medications, such as atazanavir, nelfinavir, or rilpivirine-containing products, as this is prohibited by regulators.

Age and Physiological Status

Population Group Regulatory Eligibility Status
Adults, Adolescents, Children Approved for use in patients 1 year of age and older under labeled conditions.
Infants (Under 1 Year) Use is not established; generally not recommended.
Pregnancy Not recommended; to be used only if the benefit is considered strictly necessary.
Breastfeeding Not recommended; a decision must be made to discontinue nursing or the drug.

Condition-Specific Eligibility

Use is restricted in patients with moderate or severe hepatic impairment (liver disease), where official labels recommend caution and a dose reduction may be necessary. Use is generally not restricted in patients with renal (kidney) impairment.

What should I know about interactions with other medicines?

Laprazol Interactions with other medicines and products

Laprazol (Lansoprazole) can interact with other medicinal products primarily through two mechanisms: significantly reducing gastric acid secretion and influencing Cytochrome P450 (CYP) enzyme activity.


Pharmacokinetic Interaction Overview

Classification Mechanism/Condition
Do Not Combine (Contraindicated) Rilpivirine-containing products; Atazanavir.
Use With Caution (Requires Monitoring) Warfarin, Methotrexate (especially high-dose), Tacrolimus, Digoxin, Theophylline.
Reduced Absorption Drugs requiring acidic gastric pH for absorption (e.g., Ketoconazole, Itraconazole, Iron salts, Ampicillin esters).
Reduced Efficacy Clopidogrel (due to reduced formation of the active metabolite by CYP2C19).

For atazanavir and rilpivirine, co-administration is strictly avoided due to the risk of substantially decreased drug exposure, potentially leading to a loss of therapeutic effect and the development of drug resistance. Concomitant use with warfarin requires close monitoring of INR and prothrombin time, as altered metabolism may affect the anticoagulant effect. Similarly, tacrolimus concentrations must be monitored and dose adjustments may be necessary. High-dose methotrexate requires temporary withdrawal of Laprazol therapy due to the risk of elevated and prolonged serum concentrations of methotrexate. Long-term use of Laprazol may also be associated with conditions such as hypomagnesemia and increased risk of bone fractures.

Mechanism of Action

The Laprazol Mechanism of Action: How it Works

Laprazol is an irreversible proton pump inhibitor that blocks the final step of acid secretion, resulting in a significant decrease in gastric pH. Its mechanism involves a targeted chemical process to achieve sustained pH modulation in the stomach.


Irreversible Blockade of the Gastric Proton Pump

Laprazol's primary biological target is the H^+, K^+-ATPase enzyme (the proton pump) in the gastric parietal cells. The drug, once activated, forms a covalent bond with the enzyme, permanently shutting down the movement of hydrogen ions ( H^+) and halting acid secretion. This action contributes to the elevation of the stomach's pH.


Acid-Dependent Activation Cascade

Laprazol is a prodrug that must first diffuse into the highly acidic canaliculi of the parietal cell. Here, the low pH converts it into its active sulfenamide form, which is the actual inhibitor. This activation process localizes the inhibitory effect primarily to the site of acid production.


Sustained Suppression of Secretion

Because the inhibition is permanent, the return of full acid-secreting function relies solely on the natural synthesis of new proton pumps. This biological turnover rate dictates the duration of the physiological effect, which provides a sustained suppression of both basal and stimulated acid secretion.

Dosage and Administration Information

Laprazol (Lansoprazole) is administered by the oral route as delayed-release capsules, orally disintegrating tablets (ODTs), or oral suspension, and can also be given by intravenous (IV) infusion when oral intake is not feasible. The oral forms are generally directed to be taken before eating, typically 30 to 60 minutes prior to the first meal of the day.

The standard adult regimen is most commonly 15 mg or 30 mg taken once daily. Usage is structured into defined time periods: short-term courses for acute needs generally run for 4 to 8 weeks, while low-dose maintenance may be prescribed for chronic management. Non-prescription use for frequent heartburn is officially limited to intermittent 14-day courses. Higher daily doses, such as those used for pathological hypersecretory conditions, may necessitate a divided daily schedule.

Procedurally, the delayed-release capsules and tablets must not be crushed, chewed, or opened to protect the enteric coating necessary for proper drug delivery. The powder for IV use requires specific reconstitution and slow infusion over a set duration. If a daily dose is missed, it should be taken immediately upon recall, unless it is near the next scheduled time, in which case the missed dose is skipped without taking a double dose. Standard guidelines stipulate dose adjustments for certain patient populations, notably requiring a reduction in the maximum daily dose for individuals with severe hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Laprazol (Lansoprazole)

Evidence for Use in Gastroesophageal Reflux Disease (GERD) and Erosive Esophagitis

Laprazol was studied for its application in exploring management of a related condition called Erosive Esophagitis (EE), where the esophagus lining is damaged by acid, as well as addressing symptoms of Gastroesophageal Reflux Disease (GERD). This research primarily involved short-term, randomized controlled trials (RCTs). These studies included both comparisons against inactive treatments (placebo) and comparisons against other medicines used in acid suppression research.

Researchers examined patient-reported outcomes describing perceived discomfort, such as the frequency and intensity of heartburn, as well as the healing of the esophageal lining, which was tracked using special imaging. The findings describe patterns observed in the studies over the short follow-up periods, usually between four and eight weeks. Studies also explored outcomes related to the maintenance of the esophagus lining, often using extended-duration maintenance trials.

Evidence for Use in Healing and Prevention of Peptic Ulcers

Laprazol was evaluated in trials focused on outcomes related to healing peptic ulcers. The research primarily used RCTs to compare different acid-suppressing strategies. Studies monitored the size and status of the ulcers using endoscopy and tracked patient-reported outcomes describing perceived discomfort, such as abdominal pain. Studies reported how pain symptoms evolved in the observed populations during these treatment phases.

Separately, other trials examined research focused on the recurrence of ulcers; these maintenance studies often extended follow-up durations for six months or longer.

What Remains Uncertain About the Research Evidence

While a large research base exists, scientific evidence is rarely absolute. The evidence quality varies across studies, particularly between short-term healing trials and long-term observational follow-up. One key gap is that long-term effects are not fully established by prospective, controlled trials beyond the defined periods of a few months to a year. For rare conditions, sample sizes were modest, contributing to lower statistical certainty. The research does not determine whether an individual will respond similarly to the group patterns observed in the studies; research is ongoing to provide more context.

Key Studies & References Are proton pump inhibitors the first choice for acute treatment of gastric ulcers: a meta analysis of randomized clinical trials

Frequently Asked Questions (FAQ)

Common questions about Laprazol (FAQ)


Q: If I stop taking Laprazol, is it common for my original symptoms to return?

Studies and official information indicate that after discontinuing this medicine, symptoms—particularly those related to increased acid production—may return for a temporary period. This is sometimes referred to as rebound hypersecretion. This return of symptoms may be observed even after short courses of treatment.


Q: Is Laprazol suitable for elderly patients, according to safety data?

Regulatory documents mention that elderly patients may experience a slight increase in sensitivity to the medicine's effects compared to younger adults. However, official safety data does not typically recommend a specific dose change based on age alone for this population.


Q: Can a patient with an allergy to other PPIs safely take Laprazol?

According to official guidance, use is generally restricted by official guidance for individuals with known hypersensitivity to medicines in the Proton Pump Inhibitor (PPI) class. This is based on a general safety precaution to prevent severe allergic responses.


Q: Does Laprazol affect the effectiveness of hormonal birth control?

Studies cited in official product information have examined this potential interaction. The research indicates that Laprazol (lansoprazole) does not appear to affect the bioavailability (how much drug reaches the bloodstream) or effectiveness of low-dose hormonal oral contraceptives.


Q: Is there a required time gap between taking Laprazol and taking iron or calcium supplements?

Official documents state that Laprazol reduces stomach acid, which can lessen the body's ability to absorb certain nutrients, including iron. This potential decrease in absorption is why a time gap between administrations is often discussed in clinical practice.


Q: How long has the active ingredient in Laprazol been in use clinically?

The active ingredient in this medicine, lansoprazole, has been in clinical use for several decades. It received its initial approval from the U.S. Food and Drug Administration (FDA) in May 1995.


Q: Why is Laprazol sometimes prescribed by doctors alongside antibiotic treatment?

Laprazol is officially indicated for the eradication of Helicobacter pylori, a bacterium that can cause ulcers. In these cases, it is prescribed concurrently with specific antibiotic therapies, such as amoxicillin and clarithromycin, to help heal the ulcers and prevent their return.


Q: Is a generic version of Laprazol available?

Yes, the active ingredient in Laprazol, lansoprazole, is available in generic form. Official regulatory bodies have approved generic versions of the delayed-release capsules and orally disintegrating tablets.


Q: Do official documents mention the possibility of withdrawal symptoms when stopping Laprazol?

Regulatory-associated guidance acknowledges a temporary effect called rebound hypersecretion when PPIs are discontinued. This means the stomach temporarily increases acid production above pre-treatment levels, which may cause reflux symptoms to return.


Q: How does the effect of Laprazol differ from the fast relief provided by standard antacids?

Laprazol and antacids work in fundamentally different ways. Antacids provide fast relief by immediately neutralizing existing stomach acid. Laprazol, as a Proton Pump Inhibitor, works by blocking the acid pump itself, with effects that build up over several hours but last much longer.


Q: Can Laprazol be taken by people who are sensitive to lactose or gluten?

The official product information specifies that the medicine contains sucrose (sugar). For patients with rare hereditary problems like fructose intolerance or glucose-galactose malabsorption, official labeling states that use is generally restricted. Information regarding gluten sensitivity is not typically provided in the main regulatory documents.


Q: Does Laprazol have any effects on blood pressure or heart rate?

The medicine is officially documented to increase the risk of hypomagnesemia (low magnesium) with long-term use. This condition can, in turn, cause changes in the heart's electrical activity, potentially leading to an abnormal heart rhythm or a fast heartbeat.


Q: How quickly is Laprazol eliminated from the body?

The drug's plasma elimination half-life—the time it takes for half the drug to be processed—is quite short, typically between 1 and 2 hours. However, because the medicine acts by permanently blocking the acid pumps, its therapeutic effect on stomach acid lasts much longer than its short presence in the bloodstream.


Q: Is there a difference between Laprazol tablets and Laprazol capsules?

Official regulatory information describes several available forms, including delayed-release capsules and orally disintegrating tablets (ODTs). The difference lies primarily in the form of administration and the inactive ingredients, or excipients, such as the presence of a source of phenylalanine in the ODTs.

How should Laprazol be stored and disposed of?

Official Storage and Disposal Requirements

Laprazol (lansoprazole) must be stored according to specific regulatory guidelines to maintain the stability of its delayed-release formulation. Official labeling mandates storage at controlled room temperature, typically 20 –25 C (68 –77 F). The product must be strictly protected from moisture and high heat.


  • Packaging Rules: The medicine should remain in its original, tightly closed container or package. If the product is stored in a bottle, the official labeled stability period is three months after first opening.
  • Child Safety: It is a mandatory requirement to keep Laprazol out of the reach of children.
  • Disposal Protocol: Unused or expired Laprazol should not be flushed down a toilet or drain. The official protocol advises disposal through a community drug take-back program. If one is unavailable, the medicine should be mixed with an undesirable substance (such as used coffee grounds) and placed in a sealed bag before being discarded with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Laprazol found in:

A-Z Index: